Activation of DR5 by its ligand, TNF-related apoptosis-inducing ligand (TRAIL), selectively kills cancer cells without effects on nontransformed cells, and shows manageable side effects in clinical trials10–12. This evidence concerns the gene TNFRSF10B and cancer.